Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes-Reference-Cited by-同舟云学术

Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes

Published:2006-12 Issue:3 Volume:3 Page:159-165
ISSN:1479-1641
Container-title:Diabetes and Vascular Disease Research
language:en
Short-container-title:Diabetes and Vascular Disease Research

Author:

Green Brian D¹,Flatt Peter R²,Bailey Clifford J³

Affiliation:

1. School of Biological Sciences, Queens University Belfast, Belfast, BT9 5AG, UK

2. School of Biomedical Sciences, University of Ulster, Coleraine, UK

3. School of Life and Health Sciences, Aston University, Birmingham, UK

Abstract

Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPP IV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or ‘gliptins’) have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.3132/dvdr.2006.024

Reference70 articles.

1. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides

2. CD26: A Multifunctional Integral Membrane and Secreted Protein of Activated Lymphocytes

3. Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes

4. Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents

5. GLP‐1 in NIDDM

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Exploration of ((Substituted-Phenyl-1H-Pyrazol-4-yl) Methylene) Aniline Derivatives as Potential DPP-IV Inhibitors: ADMET Screening, Molecular Docking, and Dynamics Simulations;CHEM METHODOL;2025

2. Recent Developments in Diabetes Management: Exploring Receptors, Pathways, and Compounds;BIO Integration;2025

3. Computational approaches for lead compound discovery in dipeptidyl peptidase-4 inhibition using machine learning and molecular dynamics techniques;Computational Biology and Chemistry;2024-10

4. Dipeptidyl Peptidase (DPP)-4 Inhibitors and Pituitary Adenylate Cyclase-Activating Polypeptide, a DPP-4 Substrate, Extend Neurite Outgrowth of Mouse Dorsal Root Ganglia Neurons: A Promising Approach in Diabetic Polyneuropathy Treatment;International Journal of Molecular Sciences;2024-08-15

5. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides;Current Protein & Peptide Science;2024-05